Max Krummel
@maxkrummel.bsky.social
Prof @ucsf/immunox, co-founder Solvingfor.org, partner Founderyinnovations.com, Immunologist,Immunotherapy pioneer,believer in the power of curiosity,striving to make sense of complicated things, typically enthusiastic.
How will our increasingly deep understanding of diverse immune archetypes in cancers guide our search for cures?
This perspective describes a future in which we discover drugs based on transitions of tissue/immunobiology through intermediate states, to health. authors.elsevier.com/a/1llig5TA51...
This perspective describes a future in which we discover drugs based on transitions of tissue/immunobiology through intermediate states, to health. authors.elsevier.com/a/1llig5TA51...
September 17, 2025 at 12:53 PM
How will our increasingly deep understanding of diverse immune archetypes in cancers guide our search for cures?
This perspective describes a future in which we discover drugs based on transitions of tissue/immunobiology through intermediate states, to health. authors.elsevier.com/a/1llig5TA51...
This perspective describes a future in which we discover drugs based on transitions of tissue/immunobiology through intermediate states, to health. authors.elsevier.com/a/1llig5TA51...
Many tx studies (Mujal... Azizi…)failed to validate M1/M2 signatures in vivo. Many also suspected that calling cells bearing ‘prototypical M2’ genes ‘‘immunosuppressive’ was simplistic + incorrect. Nonetheless many (us too!) leaned on the simplification. Arja addresses the reality head on…thnx JEM
December 2, 2024 at 4:11 AM
Many tx studies (Mujal... Azizi…)failed to validate M1/M2 signatures in vivo. Many also suspected that calling cells bearing ‘prototypical M2’ genes ‘‘immunosuppressive’ was simplistic + incorrect. Nonetheless many (us too!) leaned on the simplification. Arja addresses the reality head on…thnx JEM